Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers
Podcast 2: Next steps after progression in GEJ cancers: Rechallenging with VEGF-directed therapy
Post-Test/Evaluation
Questions marked with a
*
are required
18%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Edward is a 75 year-old man who presents with an ulcerating mass in the gastric body that is HER2+ and has progressed despite being on first-line therapy. Which of the following are options is most appropriate as second-line therapy?
A. Ramucirumab
B. Tipiracil/trifluridine
C. Trastuzumab deruxtecan
D. Entrectinib
Follow-up imaging finds new metastatic lesions in the liver. Which of the following statements are true regarding therapy sequencing?
A. Antiangiogenic therapy has no role in second- or third-line therapy for HER2+ cancers
B. Trifluridine/tipiracil therapy should be considered as a third-line treatment option
C. Paclitaxel + ramucirumab is a proven superior second-line treatment option
D. Multidisciplinary care teams do not help maximize outcomes after first-line therapy has failed
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close
drag_indicator
highlight_off